Physician
Endocrinology
Dr. Harold E. Bays, MD
|
|
Give Review
Harold Bays practices Endocrinology. He went to University of Louisville School of Medicine. University of Louisville School of Medicine has a rank of 83 in research and a 0 in primary care He over the years received 2 awards: "Fellow (FACE)" and "Fellow (FACC)". Harold Bays is also published. He has 73 publications published. The lastest publication: "Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesit...'
Publications
- Adiposopathy and epigenetics: an introduction to obesity as a transgenerational disease.
- Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model.
- A randomized study of raisins versus alternative snacks on glycemic control and other cardiovascular risk factors in patients with type 2 diabetes mellitus.
- Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Stati...
- Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction.
- Efficacy and Safety of Alirocumab as Add-on Therapy in High-Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 4...
- Cholesterol Treatment Patterns and Cardiovascular Clinical Outcomes Associated with Colesevelam HCl and Ezetimibe.
- Adiposopathy, "Sick Fat," Ockham's Razor, and Resolution of the Obesity Paradox.
- Anti-PCSK9 Monotherapy for Hypercholesterolemia - The MENDEL-2 Randomized, Controlled Phase 3 Clinical Trial of Evolocumab.
- Single-Pill Combination of Telmisartan and Hydrochlorothiazide: Studies and Pooled Analyses of Earlier Hypertension Treatment.
- Raisins compared with other snack effects on glycemia and blood pressure: a randomized, controlled trial.
- Reduction in lipoprotein (a) with the PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of over 1300 patients in 4 phase 2 trials.
- Canagliflozin, a sodium glucose co-transporter 2 inhibitor: effects in overweight and obese subjects without diabetes mellitus.
- Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus.
- Effects of Naltrexone Sustained- Release/Bupropion Sustained Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With T...
- The Editor's Roundtable: Hypertriglyceridemia.
- Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholes...
- Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia.
- Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARIN...
- Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies.
- Chitin-glucan fiber effects on oxidized low-density lipoprotein: a randomized controlled trial.
- Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabete...
- Planning a clinical trial.
- Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
- Effectiveness and safety of laropiprant on niacin-induced flushing.
- Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
- Long-term (52-78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients.
- Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
- Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprote...
- Colesevelam HCI Added to Background Metformin Therapy in Patients With Type 2 Diabetes Mellitus: A Pooled Analysis From Three Clinical Studies.
- MBX-8025, A Novel Peroxisome Proliferator Receptor-{delta} Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Ator...
- Adiposopathy is "sick fat" a cardiovascular disease?
- Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd,...
- Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
- Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome.
- Colesevelam hydrochloride powder for oral suspension versus cholestyramine powder for oral suspension: comparison of acceptability and tolerability.
- Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
- Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for co...
- The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
- Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.
- The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
- Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
- Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
- Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-control...
- "Sick fat," metabolic disease, and atherosclerosis.
- Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia.
- Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high ris...
- Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.
- Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
- The 'forgotten' bile acid sequestrants: is now a good time to remember?
- Safety considerations with omega-3 fatty acid therapy.
- Safety considerations with niacin therapy.
- Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
- Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholest...
- Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin.
- Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin.
- Metabolic syndrome: what might be occurring?
- Current and investigational antiobesity agents and obesity therapeutic treatment targets.
- Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day.
- Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin an...
- Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.
- Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
- Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus.
- National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - executive summary.
- National lipid association annual summary of clinical lipidology 2015.
- Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo-controlled study.
- Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesit...
- Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
- Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Ana...
- National Lipid Association Annual Summary of Clinical Lipidology 2016.
- Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association.
- An assessment by the Statin Intolerance Panel: 2014 update.
Schools
University Of Louisville
University Louisville School Of Med
Doctors Specialties
- Endocrinology
Accepted Insurances
Awards
- Fellow (FACE)
- Fellow (FACC)
Education
-
University of Louisville -
University of Louisville School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Lal K. Tanwani, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nisha R. Varghese, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ramana V. Chennubhotla, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Stephen F. Cavanah, MD
This Doctor is OpenDoctor Recommended.
|